NewAmsterdam Pharma Company N.V.
NAMS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $19 | $3 | $13 |
| % Growth | -98.2% | 542.9% | -76.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $19 | $3 | $13 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $31 | $28 | $45 | $35 |
| G&A Expenses | $25 | $27 | $27 | $35 |
| SG&A Expenses | $25 | $27 | $27 | $24 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$11 |
| Other Operating Expenses | $0 | $0 | $0 | -$3 |
| Operating Expenses | $55 | $55 | $72 | $56 |
| Operating Income | -$55 | -$36 | -$69 | -$43 |
| % Margin | -15,845.7% | -186.1% | -2,314.5% | -338.5% |
| Other Income/Exp. Net | -$17 | $18 | $29 | -$49 |
| Pre-Tax Income | -$72 | -$17 | -$40 | -$92 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$72 | -$17 | -$40 | -$92 |
| % Margin | -20,691.1% | -90.7% | -1,327.3% | -721.7% |
| EPS | -0.61 | -0.15 | -0.34 | -0.98 |
| % Growth | -306.7% | 55.9% | 65.3% | – |
| EPS Diluted | -0.61 | -0.15 | -0.34 | -0.98 |
| Weighted Avg Shares Out | 119 | 113 | 116 | 97 |
| Weighted Avg Shares Out Dil | 119 | 113 | 116 | 97 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $7 | $7 | $4 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$72 | -$36 | -$69 | -$112 |
| % Margin | -20,672.7% | -185.9% | -2,312.7% | -874.5% |